GMED Stands Out as the Weak Link Among Spine Peers

GMED fell 4.1% over the past week while the median move among its closest correlated peers was just -0.5%, making it the clear laggard in a group that largely held its ground.

Short interest in Globus Medical is genuinely elevated and has been building. At 7.5% of free float, it ranks meaningfully above most peers heading into the November 3 print. The monthly trend shows a 6.8% rise over October, even as the past week brought some covering, down 8.1% in the last five sessions to roughly 8.36 million shares short. Borrow costs remain low at 0.52%, and availability is comfortable at 321%, well above the level that would signal any squeeze pressure in the lending pool. The options market tells a different story. The put/call ratio has dropped to 0.29, more than two standard deviations below its 20-day average of 0.32, its lowest reading in months. That extreme skew toward calls is unusual for a stock down 5.9% in a single session on October 30, and it suggests at least some positioning for a recovery rather than further downside.

The analyst community has spent much of 2026 cutting targets on GMED without abandoning positive ratings. RBC lowered its target to $85 in early October, still maintaining Outperform. Before that, Truist and Piper Sandler both trimmed to $100 from $115 over the summer, and Wells Fargo pulled back to $99. UBS initiated at Neutral with an $82 target in July. The direction of travel is clearly downward on targets, even if most firms have not walked away from buy-equivalent ratings. The bull case rests on Q1's strong execution: $760 million in revenue, 11.2% organic growth, and raised full-year EPS guidance of $4.70 to $4.80. Bears are more focused on whether ExcelsiusGPS robotics adoption can sustain that trajectory and whether larger competitors including SYK and ZBH are gaining ground in spine. On valuation, the stock trades at roughly 15.6 times trailing earnings, a level that leaves little margin for execution slips.

The ownership picture has some movement worth noting. BlackRock filed an updated 13G on October 27, reducing its stake from 9.1% to 8.0%. Vanguard Capital Management also filed on October 30, disclosing a drop from 5.22% to 4.43%. Neither signals activist concern, both are passive holders adjusting around index thresholds, but the direction of institutional flow is outward. Retail attention, meanwhile, has spiked: the Wikipedia pageviews signal registered a z-score of 3.1 against GMED's own 90-day history as of October 25, a sign of elevated public attention that tends to track volatility rather than predict direction.

Among peers, SIBN gained nearly 4% on the week and SYK added 1.5%, while BSX dropped 7.2% and GMED itself was the second-worst performer in the basket. The print on November 3 will test whether GMED's underperformance relative to the group reflects a company-specific concern about the durability of its growth algorithm, or simply the weight of target-price reductions catching up with a stock that had run well ahead of revised Street estimates.